8-K: CONMED Secures New $750 Million Credit Facilities, Extends Debt Maturity to 2030

CONMED Corporation has entered into an Eighth Amended and Restated Credit Agreement, securing new credit facilities totaling $750 million and extending the maturity of its term loan and revolving credit facilities to June 10, 2030.

Summary

• CONMED Corporation and its subsidiary Linvatec Nederland B.V. executed an Eighth Amended and Restated Credit Agreement on June 10, 2025, replacing the previous agreement dated July 16, 2021.
• The new agreement provides secured facilities including a $550.0 million U.S. dollar revolving credit facility, a $100.0 million multicurrency revolving credit facility, and a $100.0 million term loan facility.
• Proceeds from the new $100.0 million term loan facility were used to repay outstanding amounts under the prior term loan facility.
• An additional $16.0 million was drawn from the new revolving credit facilities to repay outstanding amounts under the previous revolving credit facilities.
• The maturity date for both the term loan and revolving credit facilities has been extended to June 10, 2030.
• Key covenant changes include the removal of the fixed charge coverage ratio covenant and the introduction of a minimum interest coverage ratio, which must be not less than 2.75 to 1.00, tested quarterly.
• Mandatory prepayments in case of excess cash flow have been removed.
• Applicable interest rate margins prior to the first adjustment date are 1.125% per annum for Term Benchmark Loans, 0.125% per annum for ABR Loans, and 1.125% per annum for Loans denominated in Sterling.
• The agreement includes financial covenants requiring a consolidated senior secured leverage ratio not greater than 3.75 to 1.00 and a consolidated total leverage ratio not greater than 5.50 to 1.00, with certain step-ups available for material acquisitions.
• A new minimum liquidity covenant will commence 91 days prior to the earliest scheduled maturity date of CONMED's convertible notes, requiring liquidity of at least $75 million plus the aggregate principal amount of early maturing debt if it exceeds $200 million.
• Borrowings under the Credit Agreement are secured by assets and rights of CONMED and certain of its subsidiaries, as detailed in the Amended and Restated Guarantee and Collateral Agreement.

Sentiment

Score: 7

Explanation: The new credit agreement significantly extends debt maturities and provides increased financial flexibility by removing certain restrictive covenants and allowing for leverage ratio step-ups for acquisitions. These terms are generally favorable for the company's long-term strategic planning and growth initiatives, indicating a positive financial management outcome.

Positives

• The maturity of the term loan and revolving credit facilities has been extended by approximately five years to June 10, 2030, providing long-term financial stability and predictability.
• The fixed charge coverage ratio covenant has been removed, offering the company greater operational flexibility and potentially reducing constraints on certain financial activities.
• Mandatory prepayments in case of excess cash flow have been eliminated, allowing CONMED to retain more cash for reinvestment, strategic initiatives, or other corporate purposes.
• The company maintains access to substantial revolving credit facilities ($550.0 million USD and $100.0 million multicurrency), providing ample liquidity for general corporate purposes, including acquisitions and stock repurchases.

Negatives

• A new minimum interest coverage ratio of 2.75 to 1.00 has been introduced, adding a new financial constraint that the company must continuously monitor and comply with.
• A minimum liquidity covenant has been added, requiring CONMED to maintain at least $75 million plus the aggregate principal amount of early maturing debt (if over $200 million) under certain conditions, which could limit cash deployment flexibility.

Risks

• Failure to comply with the consolidated senior secured leverage ratio (not greater than 3.75 to 1.00, with potential step-ups to 4.25 to 1.00 for material acquisitions) could trigger an Event of Default.
• Failure to comply with the consolidated total leverage ratio (not greater than 5.50 to 1.00, with potential step-ups to 6.00 to 1.00 for material acquisitions) could trigger an Event of Default.
• Failure to maintain the minimum interest coverage ratio of 2.75 to 1.00 could lead to an Event of Default.
• Failure to maintain the minimum liquidity covenant (at least $75 million plus early maturing debt if over $200 million) could result in an Event of Default.
• Defaults relating to other indebtedness of at least $50.0 million in aggregate could trigger an Event of Default under the new credit agreement.
• Judgments not covered by insurance in excess of $50.0 million in aggregate being rendered against CONMED or its subsidiaries could lead to an Event of Default.
• The acquisition by any person or group of more than 40% of the outstanding common stock of CONMED, or the board of directors ceasing to consist of a majority of Continuing Directors, could constitute an Event of Default.
• Incurrence of certain ERISA liabilities that would reasonably be expected to have a material adverse effect could trigger an Event of Default.
• Pledging of Capital Stock of Foreign Subsidiaries is limited to 65% of voting stock to avoid adverse tax consequences, which could impact the full collateralization of debt.
• Repatriation of Net Cash Proceeds from Asset Sales or Recovery Events by Foreign Subsidiaries may be prohibited or result in material adverse tax consequences, potentially limiting the company's ability to use such proceeds for debt prepayment.

Future Outlook

The new credit agreement provides CONMED with enhanced financial flexibility and extended debt maturities, supporting its general corporate purposes, including potential future acquisitions and repurchases of its Capital Stock. The removal of mandatory prepayments from excess cash flow allows the company to retain more capital for strategic deployment.

Management Comments

• Todd W. Garner, Executive Vice President, Finance & Chief Financial Officer, and Johonna Pelletier, Vice President, Tax and Treasurer, signed the Eighth Amended and Restated Credit Agreement on behalf of CONMED Corporation, indicating management's endorsement of the new financial terms and structure.

Industry Context

This debt refinancing and amendment is a standard financial management activity for publicly traded companies like CONMED. The extended maturity dates and adjusted covenants reflect the company's ongoing efforts to optimize its capital structure and secure favorable lending terms in the current market environment. The flexibility gained, particularly the removal of the fixed charge coverage ratio and excess cash flow prepayments, aligns with a strategy to support growth initiatives and capital allocation decisions common in the medical technology sector.

Comparison to Industry Standards

• The consolidated senior secured leverage ratio of 3.75x (with step-ups to 4.25x for material acquisitions) and consolidated total leverage ratio of 5.50x (with step-ups to 6.00x) are within the typical range for medical technology companies, providing operational headroom for growth and M&A activities.
• The minimum interest coverage ratio of 2.75x is a common financial safeguard in credit agreements, ensuring the company's ability to service its debt obligations.
• The extension of debt maturities to five years is a positive outcome, aligning with common long-term financing strategies in the industry to reduce refinancing risk.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from extended debt maturities, which reduce refinancing risk and provide greater financial stability. The removal of mandatory excess cash flow prepayments and flexibility for acquisitions could lead to increased capital returns (e.g., stock repurchases) or growth-driven value creation.
• Lenders/Creditors: The new credit agreement provides a clear framework for the company's debt obligations, with updated covenants (leverage ratios, interest coverage, liquidity) designed to manage risk. The security interests on assets remain in place, protecting their investment.
• Employees: While not directly impacted by the credit agreement, a more stable financial position and potential for strategic growth through acquisitions can lead to job security and opportunities.
• Customers and Suppliers: Financial stability and the ability to invest in growth can lead to more reliable business relationships and potentially enhanced product offerings or services.

Next Steps

• CONMED will make quarterly installment payments on the Tranche A Term Loans, with the first payment due September 30, 2025.
• The company must ensure ongoing compliance with the new financial covenants, including the consolidated senior secured leverage ratio, consolidated total leverage ratio, minimum interest coverage ratio, and minimum liquidity covenant.
• The company may utilize the new credit facilities for general corporate purposes, including potential future acquisitions and repurchases of its Capital Stock.
• CONMED and its subsidiaries are committed to maintaining and enforcing policies and procedures to ensure compliance with Anti-Corruption Laws and applicable Sanctions.
• The company must also ensure compliance with Outbound Investment Rules.

Key Dates

Recommendation

Keywords

CONMED Corporation, CNMD, Credit Agreement, Debt Refinancing, Revolving Credit Facility, Term Loan, Financial Covenants, SEC Filing, 8-K, Corporate Finance, JPMorgan Chase, Corporate Debt, Liquidity, Leverage Ratio, Interest Coverage Ratio